Exactly one month ago, the article "Cellectis is preparing its IPO in the U.S" explained…
The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
Editor's Picks for CAR-T
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer?
- From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah
- Gene-Edited T Cell Therapy Players Battle Safety Doubts
- How European Startups Have Advanced Cancer T-Cell Therapy in 2020
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.Go to Report